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Perspective
A
lthough randomized trials 
provide key guidance for 
how we practice medicine, 
trust in their published results has 
been eroded in recent years due to 
several high-profile cases of alleged 
data suppression, misrepresentation, 
and manipulation [1–5, 39]. While 
most publicized cases have involved 
pharmaceutical industry trials, 
accumulating empiric evidence has 
shown that selective reporting of results 
is a systemic problem afflicting all 
types of trials, including those with no 
commercial input [6]. These examples 
highlight the harmful potential impact 
of biased reporting on patient care, and 
the violation of ethical responsibilities 
of researchers and sponsors to 
disseminate results accurately and 
comprehensively. 
Biased reporting arises when two 
main decisions are made based on the 
direction and statistical significance of 
the data—whether to publish the trial 
at all, and if so, which analyses and 
results to report in the publication. 
Strong evidence for the selective 
publication of positive trials has been 
available for decades [7,8]. More 
recent cohort studies have focused 
on the misreporting of trials within 
publications by comparing journal 
articles either with documents from 
regulatory agencies [9–12] or with 
trial protocols from research ethics 
committees [13–16], funding agencies 
[17], research groups [18,19], and 
journals [20]. These cohort studies 
identified major discrepancies—
favorable results were often highlighted 
while unfavorable data were 
suppressed; definitions of primary 
outcomes were changed; and methods 
of statistical analysis were modified 
without explanation in the journal 
article. 
New Evidence
In a new study published in PLoS 
Medicine, Lisa Bero and colleagues 
make an important contribution to 
the growing body of evidence that 
the randomized trial literature is 
skewed towards reporting favorable 
results [9]. The researchers identified 
trials from 33 new drug applications 
(NDAs) for new molecular entities 
approved by the United States Food 
and Drug Administration (FDA) in 
2001–2002, and compared information 
from FDA reviews with journal 
articles. By including all NDAs from 
a variety of specialty fields, their 
findings have broad generalizability to 
pharmaceutical trials. 
Overall, a substantial amount of 
primary outcome data submitted to 
the FDA was found to be missing from 
the literature. One quarter of trials 
in their sample were unpublished—
predominantly those with unfavorable 
results. Not only were data suppressed 
for the unpublished trials, but an 
additional quarter of primary outcomes 
were omitted from journal articles of 
published trials. These findings are 
consistent with two recent reviews of 
FDA documents and journal articles 
[10,21], one of which was published in 
PLoS Medicine in September 2008 [21]. 
Bero and colleagues also identified 
important discrepancies between 
the primary outcomes, statistical 
analyses, and conclusions presented 
in NDAs versus those reported in 
journal articles. The vast majority of 
discrepancies favored the sponsor’s 
new drug, suggesting biased reporting. 
While it is possible that the FDA 
requested modifications to the 
sponsor’s analyses, these amendments 
should be mentioned in the FDA’s 
statistical review; should not involve 
altering primary outcomes without 
explanation in the publication; and 
would not be expected to favor the 
sponsor’s drug as often as was found in 
this study. 
Biased reporting of results from NDA 
trials is particularly concerning because 
these journal articles are the only peer-
reviewed source of information on 
recently approved drugs for health care 
providers, who will have had limited 
clinical experience with these new 
treatments. There are also substantial 
cost implications if the efficacy is 
overestimated and the drugs overused, 
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Linked Research Article
This Perspective discusses the 
following new study published in PLoS 
Medicine: 
Rising K, Bacchetti P, Bero L (2008) 
Reporting bias in drug trials submitted 
to the Food and Drug Administration: A 
review of publication and presentation. 
PLoS Med 5(11): e217. doi:10.1371/
journal.pmed.0050217
Lisa Bero and colleagues review 
the publication status of all efficacy 
trials carried out in support of new 
drug approvals from 2001 and 2002, 
and find that a quarter of trials remain 
unpublished.PLoS Medicine  |  www.plosmedicine.org 1534 November 2008  |  Volume 5  |  Issue 11  |  e230
as new molecular entities are among 
the most expensive pharmaceuticals on 
the market [22]. 
The Need for Increased 
Transparency
Since the interests of patients are of 
utmost importance, it is difficult to 
justify why health care providers and 
policy makers should have access to 
only a biased subset of information 
that is substantially different from 
that which regulatory agencies have 
at their disposal. Bero and colleagues’ 
study highlights the importance of 
public access to key documents that 
have traditionally been deemed 
confidential—regulatory agency 
submissions and trial protocols. Both 
types of documents have unique 
properties that complement each other. 
Regulatory agency submissions 
represent the final description of how 
the trial was conducted and analyzed 
prior to journal publication. However, 
details from these submissions are not 
publicly available in most countries. 
Although summaries of FDA reviews 
are posted on the FDA Web site, their 
content and availability is variable, and 
sections are often redacted [9,21,23]. 
Furthermore, regulatory agency 
submissions are prepared by companies 
after data analysis and may themselves 
be subject to biased reporting. Finally, 
only devices, pharmaceuticals, and 
biological agents require regulatory 
approval in the United States and 
other countries, meaning that trials 
examining other types of interventions 
(e.g., surgery, education)—which 
constitute 20% of published 
randomized trials [24]—would be 
excluded from reviews of regulatory 
agency documents. Pharmaceutical 
trials conducted post-approval would 
also be missed. 
On the other hand, protocols 
constitute the most comprehensive 
description of study design prior 
to trial inception. Their content 
therefore cannot be influenced by 
the study results. However, access to 
trial protocols is particularly difficult 
to obtain [25,26]. As with summaries 
of FDA reviews, their content is 
also highly variable and often lacks 
sufficient detail [13–18,20]. The 
SPIRIT initiative (Standard Protocol 
Items for Randomized Trials) aims to 
address these deficiencies by producing 
evidence-based recommendations for 
key information to include in a trial 
protocol [27]. 
Time for Action
It is clear that the trial literature is 
biased, facilitated in part by limited 
oversight and difficulty in accessing 
detailed trial documents. Ongoing 
progress in trial registration and results 
disclosure represents a key initial step 
towards ensuring public access to basic 
information on trial methods and 
results [28–33]. Several journals have 
also acted by publishing protocols 
and requiring their submission with 
manuscripts [34–36]. 
However, much remains to be 
done—not only to establish reliable, 
comprehensive registration and results 
disclosure processes worldwide, but also 
to start heeding the calls for increased 
access to full protocols and regulatory 
agency submissions [14,23,33,37,38]. As 
shown by recent examples and studies 
highlighted above, misreporting of 
trials can be difficult to detect without 
access to detailed documents beyond 
what is currently available on registries 
and results databases. Only with full 
transparency can the validity of a 
randomized trial be judged.
The time has come to tackle 
the challenge of making key trial 
documents public. It has taken 
decades for trial registration and 
results disclosure to be implemented; 
hopefully, for the sake of patients, 
public access to full protocols and 
regulatory agency submissions will 
come much sooner.  
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